Is KLRA or CYTK more profitable?

Kailera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Cytokinetics -784.02% N/A -52.86%

Does the media prefer KLRA or CYTK?

In the previous week, Cytokinetics had 10 more articles in the media than Kailera Therapeutics. MarketBeat recorded 13 mentions for Cytokinetics and 3 mentions for Kailera Therapeutics. Cytokinetics' average media sentiment score of 1.00 beat Kailera Therapeutics' score of 0.32 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KLRA or KYMR?

In the previous week, Kymera Therapeutics had 4 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Kymera Therapeutics and 3 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.32 beat Kymera Therapeutics' score of 0.29 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, NUVL or KLRA?

Nuvalent is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Kailera Therapeutics N/A N/A N/A -$3.65 thousand N/A

Is NUVL or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Kailera Therapeutics N/A N/A N/A

Does the media favor NUVL or KLRA?

In the previous week, Nuvalent had 4 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Nuvalent and 3 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.32 beat Nuvalent's score of -0.01 indicating that Kailera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, KLRA or PRAX?

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A -$3.65 thousand N/A Praxis Precision Medicines N/A N/A -$303.27M -$13.37 N/A

Is KLRA or PRAX more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Praxis Precision Medicines N/A -43.02% -40.22%

Does the media prefer KLRA or PRAX?

In the previous week, Praxis Precision Medicines had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 4 mentions for Praxis Precision Medicines and 3 mentions for Kailera Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.59 beat Kailera Therapeutics' score of 0.32 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KLRA or CRNX?

In the previous week, Crinetics Pharmaceuticals had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 3 mentions for Kailera Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 0.32 beat Kailera Therapeutics' score of 0.32 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kailera Therapeutics (KLRA) Competitors

$18.55 +0.23 (+1.26%)

As of 07/17/2026 04:00 PM Eastern

Compare

KLRA vs. CYTK, KYMR, NUVL, PRAX, and CRNX

Should you buy Kailera Therapeutics stock or one of its competitors? MarketBeat compares Kailera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kailera Therapeutics include Cytokinetics (CYTK), Kymera Therapeutics (KYMR), Nuvalent (NUVL), Praxis Precision Medicines (PRAX), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.

How does Kailera Therapeutics compare to Cytokinetics?

Kailera Therapeutics (NASDAQ:KLRA) and Cytokinetics (NASDAQ:CYTK) are both mid-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Kailera Therapeutics currently has a consensus price target of $42.75, indicating a potential upside of 130.46%. Cytokinetics has a consensus price target of $99.90, indicating a potential upside of 24.59%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Kailera Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A
Cytokinetics	$105.82M	94.29	-$784.96M	-$6.84	N/A

In the previous week, Cytokinetics had 10 more articles in the media than Kailera Therapeutics. MarketBeat recorded 13 mentions for Cytokinetics and 3 mentions for Kailera Therapeutics. Cytokinetics' average media sentiment score of 1.00 beat Kailera Therapeutics' score of 0.32 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Cytokinetics	-784.02%	N/A	-52.86%

Summary

Cytokinetics beats Kailera Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Kailera Therapeutics compare to Kymera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Kailera Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kailera Therapeutics' return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Kailera Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A
Kymera Therapeutics	$51.48M	185.00	-$311.35M	-$3.57	N/A

Kailera Therapeutics presently has a consensus target price of $42.75, indicating a potential upside of 130.46%. Kymera Therapeutics has a consensus target price of $122.64, indicating a potential upside of 5.93%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Kymera Therapeutics had 4 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Kymera Therapeutics and 3 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.32 beat Kymera Therapeutics' score of 0.29 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kailera Therapeutics beats Kymera Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Kailera Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

In the previous week, Nuvalent had 4 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Nuvalent and 3 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.32 beat Nuvalent's score of -0.01 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvalent is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A

97.3% of Nuvalent shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kailera Therapeutics' return on equity of 0.00% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Kailera Therapeutics	N/A	N/A	N/A

Nuvalent currently has a consensus target price of $127.73, indicating a potential upside of 3.04%. Kailera Therapeutics has a consensus target price of $42.75, indicating a potential upside of 130.46%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kailera Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Kailera Therapeutics beats Nuvalent on 8 of the 12 factors compared between the two stocks.

How does Kailera Therapeutics compare to Praxis Precision Medicines?

Kailera Therapeutics (NASDAQ:KLRA) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

In the previous week, Praxis Precision Medicines had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 4 mentions for Praxis Precision Medicines and 3 mentions for Kailera Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.59 beat Kailera Therapeutics' score of 0.32 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics currently has a consensus price target of $42.75, indicating a potential upside of 130.46%. Praxis Precision Medicines has a consensus price target of $563.50, indicating a potential upside of 79.22%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Kailera Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kailera Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A

Summary

Praxis Precision Medicines beats Kailera Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Kailera Therapeutics compare to Crinetics Pharmaceuticals?

Kailera Therapeutics (NASDAQ:KLRA) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kailera Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Kailera Therapeutics' return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

Kailera Therapeutics has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A
Crinetics Pharmaceuticals	$18.07M	489.36	-$465.32M	-$5.13	N/A

Kailera Therapeutics presently has a consensus target price of $42.75, indicating a potential upside of 130.46%. Crinetics Pharmaceuticals has a consensus target price of $78.27, indicating a potential downside of 6.66%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kailera Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Crinetics Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Crinetics Pharmaceuticals had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 3 mentions for Kailera Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 0.32 beat Kailera Therapeutics' score of 0.32 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kailera Therapeutics and Crinetics Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Kailera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRA vs. The Competition

Export

Metric	Kailera Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$2.40B	$796.39M	$4.40B	$12.28B
Dividend Yield	N/A	4.84%	37.90%	9.34%
P/E Ratio	-0.01	1.50	23.70	23.92
Price / Sales	N/A	109.19	93.72	88.82
Price / Cash	N/A	20.06	164.16	60.41
Price / Book	N/A	8.62	12.18	6.18
Net Income	N/A	-$3.14M	$121.47M	$332.29M
7 Day Performance	-10.30%	-3.98%	-1.12%	-2.05%
1 Month Performance	-6.97%	-3.15%	-2.65%	-2.18%
1 Year Performance	N/A	32.82%	9.79%	17.67%

Kailera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRA Kailera Therapeutics	3.854 of 5 stars	$18.55 +1.3%	$42.75 +130.5%	N/A	$2.40B	N/A	N/A	145	News Coverage Short Interest Increase Gap Down
CYTK Cytokinetics	3.2562 of 5 stars	$84.87 -1.4%	$99.90 +17.7%	+115.4%	$10.56B	$88.04M	N/A	250	News Coverage Positive News Insider Trade Options Volume
KYMR Kymera Therapeutics	1.4642 of 5 stars	$119.35 +0.3%	$121.41 +1.7%	+150.7%	$9.82B	$39.21M	N/A	170	Analyst Forecast
NUVL Nuvalent	2.2547 of 5 stars	$123.90 +0.1%	$127.73 +3.1%	N/A	$9.79B	N/A	N/A	40	News Coverage Analyst Upgrade
PRAX Praxis Precision Medicines	3.2562 of 5 stars	$324.99 -2.4%	$569.63 +75.3%	+483.9%	$9.06B	$8.55M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRA) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kailera Therapeutics (KLRA) Competitors

KLRA vs. CYTK, KYMR, NUVL, PRAX, and CRNX

How does Kailera Therapeutics compare to Cytokinetics?

Summary

How does Kailera Therapeutics compare to Kymera Therapeutics?

Summary

How does Kailera Therapeutics compare to Nuvalent?

Summary

How does Kailera Therapeutics compare to Praxis Precision Medicines?

Summary

How does Kailera Therapeutics compare to Crinetics Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kailera Therapeutics (KLRA) Competitors

KLRA vs. CYTK, KYMR, NUVL, PRAX, and CRNX

How does Kailera Therapeutics compare to Cytokinetics?

Do analysts recommend KLRA or CYTK?

Which has preferable earnings and valuation, KLRA or CYTK?

Does the media prefer KLRA or CYTK?

Is KLRA or CYTK more profitable?

Summary

How does Kailera Therapeutics compare to Kymera Therapeutics?

Is KLRA or KYMR more profitable?

Which has stronger valuation and earnings, KLRA or KYMR?

Do analysts recommend KLRA or KYMR?

Does the media prefer KLRA or KYMR?

Summary

How does Kailera Therapeutics compare to Nuvalent?

Does the media favor NUVL or KLRA?

Which has better earnings & valuation, NUVL or KLRA?

Do institutionals & insiders believe in NUVL or KLRA?

Is NUVL or KLRA more profitable?

Do analysts recommend NUVL or KLRA?

Summary

How does Kailera Therapeutics compare to Praxis Precision Medicines?

Does the media prefer KLRA or PRAX?

Do analysts rate KLRA or PRAX?

Do institutionals & insiders have more ownership in KLRA or PRAX?

Is KLRA or PRAX more profitable?

Which has better earnings and valuation, KLRA or PRAX?

Summary

How does Kailera Therapeutics compare to Crinetics Pharmaceuticals?

Do institutionals and insiders believe in KLRA or CRNX?

Is KLRA or CRNX more profitable?

Which has better valuation & earnings, KLRA or CRNX?

Do analysts prefer KLRA or CRNX?

Does the media refer more to KLRA or CRNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools